Table 2.
Incidence and duration of secondary outcomes within 60 days of hematopoietic stem cell transplantation in the two groups of study patients
| Outcomes | Study groups | P value | |
|---|---|---|---|
| Vitamin A supplementation (n = 15) | Non-vitamin A supplementation (n = 15) | ||
| Febrile neutropenia, n (%) | 11 (73.3) | 11 (73.3) | 1 |
| Oral mucositis, n (%) | 14 (93.3) | 15 (100) | 1 |
| Oral mucositis severity grade 3–4, n (%) | 6 (40) | 9 (60) | 0.27 |
| Diarrhea, n (%) | 14 (93.3) | 14 (93.3) | 1 |
| Hemorrhagic cystitis, n (%) | 5 (33.3) | 5 (33.3) | 1 |
| Graft-versus-host disease, n (%) | 6 (40) | 7 (46.7) | 1 |
| Bacterial infection, n (%) | 1 (6.7) | 2 (13.3) | 1 |
| Viral infection, n (%) | 10 (66.7) | 6 (40) | 0.14 |
| Day of neutrophil engraftment, mean days ± SD | 14 ± 2.8 | 14.2 ± 3.9 | 0.87 |
| Duration of febrile neutropeniaa, days | 5 (2–10) | 6.5 (1–21) | 0.8 |
| Duration of mucositis, mean days ± SD | 9 ± 3.8 | 9 ± 4.7 | 0.96 |
| Duration of diarrheaa, days | 11.5 (2–44) | 15.5 (2–37) | 0.42 |
| Duration of need of TPN, days ± SD | 13 ± 7.1 | 11 ± 6.6 | 0.42 |
| Duration of hospitalization after day 0a, days | 29 (18–83) | 24 (15–54) | 0.13 |
| Mortality, n (%) | 0 | 2 (13.3) | 0.48 |
aMedian (min–max)
SD standard deviation, TPN total parenteral nutrition